![Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study | SpringerLink Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-019-00909-6/MediaObjects/12325_2019_909_Fig1_HTML.png)
Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study | SpringerLink
![Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer | Journal for ImmunoTherapy of Cancer Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/2/e002100/F7.large.jpg)
Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer | Journal for ImmunoTherapy of Cancer
![A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer - ScienceDirect A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1556086415305153-gr1.jpg)
A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer - ScienceDirect
![Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)† - Annals of Oncology Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)† - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/e9258ca8-ad6d-4d07-a3e2-5428e63fc2a4/gr1.jpg)
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)† - Annals of Oncology
![Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for treatment of non-small cell lung cancer - ScienceDirect Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for treatment of non-small cell lung cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332221004984-ga1.jpg)
Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for treatment of non-small cell lung cancer - ScienceDirect
![Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents | British Journal of Cancer Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2012.357/MediaObjects/41416_2012_Article_BFbjc2012357_Fig1_HTML.jpg)
Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents | British Journal of Cancer
![Randomized study of individualized pharmacokinetically‐guided dosing of paclitaxel compared with body‐surface area dosing in Chinese patients with advanced non‐small cell lung cancer - Zhang - 2019 - British Journal of Clinical Pharmacology - Randomized study of individualized pharmacokinetically‐guided dosing of paclitaxel compared with body‐surface area dosing in Chinese patients with advanced non‐small cell lung cancer - Zhang - 2019 - British Journal of Clinical Pharmacology -](https://bpspubs.onlinelibrary.wiley.com/cms/asset/ca2685cb-d6e2-4a06-b515-6e38b2a2e629/bcp13982-fig-0003-m.jpg)
Randomized study of individualized pharmacokinetically‐guided dosing of paclitaxel compared with body‐surface area dosing in Chinese patients with advanced non‐small cell lung cancer - Zhang - 2019 - British Journal of Clinical Pharmacology -
![Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer - Gota - 2021 - Cancer Medicine - Wiley Online Library Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer - Gota - 2021 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/a0c30911-26f2-4020-8039-1a6dee4ea419/cam43865-fig-0001-m.jpg)
Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer - Gota - 2021 - Cancer Medicine - Wiley Online Library
![Paclitaxel | CAS:33069-62-4 | Antineoplastic agent | Diterpenoids | High Purity | Manufacturer BioCrick Paclitaxel | CAS:33069-62-4 | Antineoplastic agent | Diterpenoids | High Purity | Manufacturer BioCrick](https://www.biocrick.com/media/images/struct/BCN4650.png)